Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis... Oncol Ther (2016) 4:275–286 DOI 10.1007/s40487-016-0032-0 ORIGINAL RESEARCH Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study . . . . Serafino Conforti Stefano Minardi Ludovica Conforti Salvatore Turano . . Stefania Bilotta Emmanuelle Vilardo Salvatore Palazzo Received: August 25, 2016 / Published online: October 7, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com minimize the impact of everolimus-associated ABSTRACT oral mucositis in patients with advanced cancer. Introduction: Stomatitis is a common and Methods: Patients receiving everolimus plus potentially dose-limiting adverse event of the exemestane for advanced breast cancer or mammalian target of rapamycin (mTOR) everolimus alone for advanced renal cancer were inhibitor therapy. To minimize dose eligible for inclusion. All patients were advised on reductions or treatment delays that may affect procedures to maintain good oral hygiene and therapeutic outcomes, management includes directed to use a dexamethasone-containing patient education, pain management galenical preparation at the first signs of strategies, and drug treatment. The aim of this mucositis. Questionnaires were administered at study was to evaluate the effectiveness of a baseline, and after cycles one, two, and three to topically-applied galenical preparation to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

Loading next page...
 
/lp/springer-journals/topical-application-of-a-galenical-formulation-for-the-management-of-nfA5hbik8h
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0032-0
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:275–286 DOI 10.1007/s40487-016-0032-0 ORIGINAL RESEARCH Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study . . . . Serafino Conforti Stefano Minardi Ludovica Conforti Salvatore Turano . . Stefania Bilotta Emmanuelle Vilardo Salvatore Palazzo Received: August 25, 2016 / Published online: October 7, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com minimize the impact of everolimus-associated ABSTRACT oral mucositis in patients with advanced cancer. Introduction: Stomatitis is a common and Methods: Patients receiving everolimus plus potentially dose-limiting adverse event of the exemestane for advanced breast cancer or mammalian target of rapamycin (mTOR) everolimus alone for advanced renal cancer were inhibitor therapy. To minimize dose eligible for inclusion. All patients were advised on reductions or treatment delays that may affect procedures to maintain good oral hygiene and therapeutic outcomes, management includes directed to use a dexamethasone-containing patient education, pain management galenical preparation at the first signs of strategies, and drug treatment. The aim of this mucositis. Questionnaires were administered at study was to evaluate the effectiveness of a baseline, and after cycles one, two, and three to topically-applied galenical preparation to

Journal

Oncology and TherapySpringer Journals

Published: Oct 7, 2016

References